On this page
Benzonatate
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Decreased Tracheobronchial Stretch Receptor Activity [PE] | PE | 4 members — no class page |
| Non-narcotic Antitussive [EPC] | EPC | 4 members — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 040682-001 | BENZONATATE | CAPSULE | BENZONATATE | Prescription | AA | ||
| 040682-002 | BENZONATATE | CAPSULE | BENZONATATE | Prescription | AA |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — no known or suspected bioequivalence problems (conventional dosage forms)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 11 | Labeling | Approved | March 21, 2023 | Standard |
| Supplement | 4 | Labeling | Approved | March 1, 2011 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | April 6, 2010 | — |
| Original application | 1 | Approved | July 30, 2007 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260323). This is the manufacturer's labelling text, not a summary and not advice.
Boxed Warning
openFDA Drug LabelingBOXED WARNING Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. Psychiatric Effects Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs. Accidental Ingestion and Death in Children Keep benzonatate out of reach of children. Accidental ingestion of benzonatate resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE ).
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Benzonatate capsules are indicated for the symptomatic relief of cough.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate Capsules should be swallowed whole. Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Hypersensitivity to benzonatate or related compounds.
Warnings
openFDA Drug LabelingWARNINGS Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. Psychiatric Effects Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate capsules in combination with other prescribed drugs. Accidental Ingestion and Death in Children Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate capsules resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE ).
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Potential Adverse Reactions to benzonatate may include: Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule. CNS: sedation; headache; dizziness; mental confusion; visual hallucinations. GI: constipation; nausea; GI upset. Dermatologic: pruritus; skin eruptions. Other: nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children. To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7. Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate, USP. Benzonatate Capsules also contain: D&C Yellow No. 10, gelatin, glycerin, methylparaben sodium and propylparaben sodium. The white imprinting ink contains the following inactive ingredients: ammonium hydroxide, isopropyl alcohol, n-butyl alcohol, propylene glycol, shellac glaze, simethicone and titanium dioxide. FDA approved dissolution test specifications differ from USP. structure
Overdosage
openFDA Drug LabelingOVERDOSAGE Intentional and unintentional overdose may result in death, particularly in children. The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion. Signs and Symptoms The signs and symptoms of overdose of benzonatate have been reported within 15 to 20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise. CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion. Treatment In case of overdose, seek seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage. Do not use CNS stimulants.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Benzonatate Capsules, USP are available as: 100 mg Oval Shape, imprint “100” with white ink, transparent yellow soft gelatin capsule NDC 23155-898-01 Bottles of 100 NDC 23155-898-05 Bottles of 500 200 mg Oblong Shape, imprint “200” with white ink, transparent yellow soft gelatin capsules NDC 23155-899-01 Bottles of 100 NDC 23155-899-05 Bottles of 500 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP. Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 51U000000461US01 Revised: 04/2024 image description
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: BENZONATATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | December 31, 2014 | Zydus Pharmaceuticals USA Inc | Failed Tablet/Capsule Specifications: Recall due to wet and/or leaking capsules. | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 65162-536-10 | 65162-536 | Amneal Pharmaceuticals LLC | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-536-10) | June 4, 2010 |
| 65162-536-50 | 65162-536 | Amneal Pharmaceuticals LLC | 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-536-50) | June 4, 2010 |
| 65162-537-10 | 65162-537 | Amneal Pharmaceuticals LLC | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-537-10) | June 4, 2010 |
| 65162-537-50 | 65162-537 | Amneal Pharmaceuticals LLC | 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (65162-537-50) | June 4, 2010 |
| 71335-3169-1 | 71335-3169 | Bryant Ranch Prepack | 21 CAPSULE, LIQUID FILLED in 1 BOTTLE (71335-3169-1) | August 11, 2026 |
| 71335-3169-2 | 71335-3169 | Bryant Ranch Prepack | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (71335-3169-2) | August 11, 2026 |
| 71335-3169-3 | 71335-3169 | Bryant Ranch Prepack | 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (71335-3169-3) | August 11, 2026 |
| 71335-3169-4 | 71335-3169 | Bryant Ranch Prepack | 10 CAPSULE, LIQUID FILLED in 1 BOTTLE (71335-3169-4) | August 11, 2026 |
| 23155-898-01 | 23155-898 | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-898-01) | September 29, 2024 |
| 23155-898-05 | 23155-898 | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-898-05) | September 29, 2024 |
| 23155-899-01 | 23155-899 | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-899-01) | September 29, 2024 |
| 23155-899-05 | 23155-899 | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-899-05) | September 29, 2024 |
| 0904-6564-60 | 0904-6564 | Major Pharmaceuticals | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (0904-6564-60) | September 4, 2007 |
| 10888-8125-1 | 10888-8125 | Patheon Softgels Inc. | 40000 CAPSULE, LIQUID FILLED in 1 BOX (10888-8125-1) | December 6, 2010 |
| 10888-8126-1 | 10888-8126 | Patheon Softgels Inc. | 25000 CAPSULE, LIQUID FILLED in 1 BOX (10888-8126-1) | October 6, 2010 |
| 63187-076-14 | 63187-076 | Proficient Rx LP | 14 CAPSULE, LIQUID FILLED in 1 BOTTLE (63187-076-14) | November 1, 2018 |
| 63187-076-20 | 63187-076 | Proficient Rx LP | 20 CAPSULE, LIQUID FILLED in 1 BOTTLE (63187-076-20) | November 1, 2018 |
| 63187-076-30 | 63187-076 | Proficient Rx LP | 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (63187-076-30) | November 1, 2018 |
| 63187-076-40 | 63187-076 | Proficient Rx LP | 40 CAPSULE, LIQUID FILLED in 1 BOTTLE (63187-076-40) | November 1, 2018 |
| 67296-2202-3 | 67296-2202 | Redpharm Drug | 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (67296-2202-3) | September 29, 2024 |
| 67296-2207-1 | 67296-2207 | Redpharm Drug | 15 CAPSULE, LIQUID FILLED in 1 BOTTLE (67296-2207-1) | September 29, 2024 |
| 68382-091-01 | 68382-091 | Zydus Pharmaceuticals USA Inc. | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (68382-091-01) | April 9, 2007 |
| 68382-247-01 | 68382-247 | Zydus Pharmaceuticals USA Inc. | 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (68382-247-01) | April 9, 2007 |
| 68382-247-05 | 68382-247 | Zydus Pharmaceuticals USA Inc. | 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (68382-247-05) | April 9, 2007 |
| 65162-536 | 65162-536 | Amneal Pharmaceuticals LLC | — | June 4, 2010 |
| 65162-537 | 65162-537 | Amneal Pharmaceuticals LLC | — | June 4, 2010 |
| 71335-3169 | 71335-3169 | Bryant Ranch Prepack | — | September 29, 2024 |
| 23155-898 | 23155-898 | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | — | September 29, 2024 |
| 23155-899 | 23155-899 | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | — | September 29, 2024 |
| 0904-6564 | 0904-6564 | Major Pharmaceuticals | — | September 4, 2007 |
| 10888-8125 | 10888-8125 | Patheon Softgels Inc. | — | January 29, 1993 |
| 10888-8126 | 10888-8126 | Patheon Softgels Inc. | — | October 30, 2007 |
| 63187-076 | 63187-076 | Proficient Rx LP | — | June 4, 2010 |
| 67296-2202 | 67296-2202 | Redpharm Drug | — | September 29, 2024 |
| 67296-2207 | 67296-2207 | Redpharm Drug | — | September 29, 2024 |
| 68382-091 | 68382-091 | Zydus Pharmaceuticals USA Inc. | — | April 9, 2007 |
| 68382-247 | 68382-247 | Zydus Pharmaceuticals USA Inc. | — | April 9, 2007 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.